Chemistry:Prexasertib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C18H19N7O2 |
| Molar mass | 365.397 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Prexasertib (LY2606368) is a small molecule checkpoint kinase inhibitor, mainly active against CHEK1, with minor activity against CHEK2. This causes induction of DNA double-strand breaks resulting in apoptosis. It was developed by Eli Lilly but the company announced in 2019 it was dropping prexasertib from active development,[1] although clinical trials continue. Research continues into the efficacy of prexasertib in treatment of acute myeloid leukemia, myelodysplastic syndrome, rhabdomyosarcoma, and medulloblastoma.[2]
References
- ↑ "Lilly dumps phase 2 cancer drugs that survived previous cull". Fierce Biotech. 30 April 2019. https://www.fiercebiotech.com/biotech/lilly-dumps-phase-2-cancer-drugs-survived-previous-cull.
- ↑ "Clinical Trials Using Prexasertib". National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services. https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/prexasertib.
 |  |
